New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
Go back to New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease| BARNES GROUP, Inc. (NYSE: B) | Delayed: 44.75 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.75 | 52 Week High | $44.27 | |||
| Open | $44.75 | 52 Week Low | $30.07 | |||
| Day High | $44.75 | P/E | 34.16 | |||
| Day Low | $44.75 | EPS | $1.31 | |||
| Volume | 72,889 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 9.59 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.59 | 52 Week High | $8.73 | |||
| Open | $9.59 | 52 Week Low | $2.86 | |||
| Day High | $9.59 | P/E | N/A | |||
| Day Low | $9.59 | EPS | $-3.82 | |||
| Volume | 2,602 | |||||
